RudaCure attended the 19th Annual Pain Therapeutics Summit held in San Diego from October 13-14, 2025, gaining insights into the latest changes and research trends in the pain therapeutics market. At the event, the company engaged in active networking with major pharmaceutical companies including Eli Lilly, Merck, Roche, and J&J, sharing clinical strategies and pain therapeutics market trends.
The summit featured presentations and discussions on the latest research into novel pain treatment targets by numerous groups, with a focus on clinical trial design for pain drug development, emerging pain targets, and advanced therapeutics. RudaCure established ongoing networks with companies showing strong interest in its innovative drug candidate RCI002, creating opportunities to discuss future licensing-out strategies and technology development directions.
The company is preparing to unveil RCI002 next year and will strengthen collaboration with global pharmaceutical companies to actively pursue global market expansion.
